Table 2

Clinical-pathological prognostic features of disease
Incident (n = 65) vs. Symptomatic (n = 130) P value OR adjusted by tumor size
Mean age 59.7 ± 0.68 vs. 56.3 ± 1.14 p < 0.05 1.04 (1.01-1.08)
Mean size (cm) 1.27 ± 0.17 vs. 2.68 ± 0.15 p < 0.001 --
Lymph node positive 21.5% vs. 48.9% p < 0.001 0.78 (0.34-1.76)
Poorly differentiated tumors 32.8 vs. 39.7% N.S. 0.56 (0.27-1.17)
ER positive 89.1% vs. 57.4% p < 0.001 4.23 (1.61-11.12)
PR positive 78.2 vs. 36.4% p < 0.001 4.60 (2.11-10.03)
In situ carcinomas 11% vs. 1.5% p < 0.001 2.44 (0.42-13.87)
Apoptosis 66.7% vs. 38.5% p < 0.05 5.06 (1.71-14.94)
Bcl-2 81.3% vs. 62.7% p < 0.05 1.39 (0.89-2.19)
c-erb-B2 26.3% vs. 23% N.S. 0.86 (0.21-3.53)
Ki67 63% vs. 52.5% N.S. 1.96 (0.93-4.09)
Delay Diagnosis- treatment (>30 days) 35.4% vs. 57% p < 0.05 0.47 (0.23-0.95)

Redondo et al.

Redondo et al. BMC Cancer 2012 12:604   doi:10.1186/1471-2407-12-604

Open Data